SLAMF7
| Official symbol: | SLAMF7 |
| Full name: | SLAM family member 7 |
| Location: | 1q23.3 |
| Also known as: | CS1, CD319, CRACC, 19A |
| Entrez ID: | 57823 |
| Ensembl ID: | ENSG00000026751 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.00 |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 1 |
|
|
| Fusions detected in 1 cancer type(s) |
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 55.93 (Percentile rank: 64.21%) |
| PubTator score: | 469.82 (Percentile rank: 92.95%) |
| Target development/druggability level: | TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action. |
| Tractability (small molecule): | N/A |
| Tractability (antibody): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
